Boston Scientific Peripheral Interventions

Exciting news! Upon close, the addition of this complementary therapy will allow us to provide treatment options for patients with both #HCC and #mCRC, which impacts 1.4 mil ppl in the US with 150k new cases diagnosed each year. We look forward to the Intera Oncology Inc. team joining BSC and PI! #InterventionalOncology

We’re excited to add the differentiated transcarotid artery revascularization (TCAR) technology into Boston Scientific’s market-leading portfolio. Carotid Artery Disease (CAD) is a rapidly growing therapy area that impacts nearly half a million new patients annually in the United States. As one company, we’re excited to bring this therapy to more patients. *Available only in US currently

In the #REALPE Analysis, the in-hospital mortality rates for #EKOS and FlowTriever were found to be comparable. Learn more about real-world evidence and BSC’s dedication to enhancing care for #pulmonaryembolism: https://bit.ly/4fNLPIJ #WhyWeEKOS

#TheraSphere #Y90 #HCC

World Diabetes Day Meet Tony, a type 1 diabetic from the UK, who faced severe leg pain that limited his mobility to just 50?metres. This pain was a sign of Peripheral Artery Disease (PAD), a cardiovascular condition common among people with diabetes. PAD can lead to critical limb?ischaemia?(CLI), a serious complication that may result in amputation if untreated.? Tony, well-informed about his diabetes, sought medical help. After two unsuccessful?balloon?angioplasties, he received?an Eluvia stent, designed to keep leg arteries open and prevent tissue regrowth. Tony has now been pain-free for years, thanks to the Eluvia stent.?Watch Tony’s inspiring journey and learn more about how innovative healthcare solutions can make a difference.? ? Learn more about PAD management and Boston Scientific’s endovascular treatment options on our EDUCARE digital platform:?https://lnkd.in/eqevzyGb #WDD2024 #DiabetesAwareness #HealthcareInnovation #PatientCare #BSCEMEA?

??? Join us next week to discuss The "Usual" Intermediate-High Risk PE Case…And "What Else” - The Usual: Standard PE case - What Else: Case with PFO present - What Else: Case with very short duration, low dose lytic protocol Register Today: https://qrco.de/ViEWebinar

#CatalyzeY90 kicks off this week! The premier, multidisciplinary, peer-to-peer education forum for #HCC. Thank you to our expert?physician?faculty Ed Kim, MD, Riad Salem, MD, Karim Halazun, MD, Anjana Pillai, MD, and Rachna Shroff, MD - stay tuned for more updates from the event.

Presented at #VIVA24 | #ELEGANCE Registry data show #Eluvia and #Ranger deliver excellent clinical outcomes in females & underrepresented racial/ethnic populations despite these patients presenting with more advanced disease. #evidencebasedmedicine #healthequity #diversity The VIVA Foundation

ROADSTER 3 30-day outcomes are in: TCAR delivers the lowest stroke rates in the first-ever independently adjudicated study for standard surgical risk patients. With TCAR's use of ENROUTE Transcarotid Stent System and ENROUTE Neuroprotection System, the 30-day data proves it’s both safe and effective in patients at standard risk of adverse events from carotid endarterectomy. #TCAR #StrokePrevention Learn More about the ROADSTER 3 Clinical Data Results: https://lnkd.in/guXb_HQW Learn More about TCAR: https://lnkd.in/gm7wVsep

What a great turnout! Thank you to the fellows/residents who attended “Morning Pulse: Navigating the Future as a NextGen Leader in #VascularHealth" this morning at #VIVA24. Big thanks to our distinguished panelists for their great guidance and discussion. The VIVA Foundation